Rapamycin attenuates load-induced cardiac hypertrophy in mice

Circulation

Volumn 107, Issue 12, 2003, Pages 1664-1670

  Shioi, Tetsuo ^a   McMullen, Julie R ^a   Tarnavski, Oleg ^a   Converso, Kimber ^a   Sherwood, Megan C ^a   Manning, Warren J ^a   Izumo, Seigo ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Heart failure; Hypertrophy; Signal transduction

Indexed keywords

INSULIN PHOSPHOINOSITIDE 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; ASCENDING AORTA; ATTENUATION; BODY WEIGHT; CELL SIZE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXPERIMENTAL MODEL; HEART LEFT VENTRICLE FAILURE; HEART SIZE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; LETHALITY; MALE; MOUSE; MUSCLE FIBER CULTURE; NONHUMAN; PRESSURE; PRIORITY JOURNAL;

ANIMALS; AORTA; CARDIOMEGALY; CONSTRICTION; FETUS; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HEART; HEMODYNAMIC PROCESSES; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIUM; MYOCYTES, CARDIAC; ORGAN SIZE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RIBOSOMAL PROTEIN S6; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, MESSENGER; SIROLIMUS;

EID: 0037382861     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000057979.36322.88     Document Type: Article

References (35)

1. Weinkove D, Leevers SJ. The genetic control of organ growth: insights from Drosophila. Curr Opin Genet Dev. 2000;10:75-80.
2. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. 2000;19:2537-2548.
3. Shioi T, McMullen JR, Kang PM, et al. Akt/Protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002:22:2799-2809.
4. Zhang H, Stallock JP, Ng JC, et al. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 2000;14:2712-2724.
5. Oldham S, Montagne J, Radimerski T, et al. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 2000;14:2689-2694.
6. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic, I: taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28:721-726.
7. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2000;15:807-826.
8. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253-262.
9. Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Opin Cell Biol. 1997;9:782-787.
10. Shima H, Pende M, Chen Y, et al. Disruption of the p70(s6 k)/p85(s6 k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 1998;17:6649-6659.
11. Chou MM, Blenis J. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signaling. Curr Opin Cell Biol. 1995;7:806-814.
12. Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro: potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res. 1995:77:1040-1052.
13. Boluyt MO, Zheng JS, Younes A, et al. Rapamycin inhibits α1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes: evidence for involvement of p70 S6 kinase. Circ Res. 1997;81:176-186.
14. Laser M, Kasi VS, Hamawaki M, et al. Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal. J Biol Chem. 1998:273:24610-24619.
15. Ding B, Price RL, Borg TK, et al. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res. 1999;84:729-734.
16. Blazar BR, Taylor PA, Snover DC, et al. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol, 1993;151:5726-5741.
17. Chen H, Qi S, Xu D, et al. The immunosuppressive effect of rapamycin on mouse small bowel transplantation. Transplantation. 1996;61:523-526.
18. Chodera A, Feller K. Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol Biopharm. 1978;16:357-360.
19. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001;59:3-16.
20. Aoki H, Richmond M, Izumo S, et al. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J. 2000;1:275-284.
21. Schultz JE, Witt SA, Nieman ML, et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest. 1999;104:709-719.
22. Tanaka M, Chen Z, Bartunkova S, et al. The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Development. 1999:126:1269-1280.
23. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med. 1998:76:725-746.
24. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995:378:785-789.
25. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2002;99:907-912.
26. Hoit BD, Ball N, Walsh RA. Invasive hemodynamics and force-frequency relationships in open- versus closed-chest mice. Am J Physiol. 1997;273:H2528-H2533.
27. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A. 1988;85:339-343.
28. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105.
29. Pham FH, Sugden PH, Clerk A. Regulation of protein kinase B and 4E-BP1 by oxidative stress in cardiac myocytes. Circ Res. 2000;86:1252-1258.
30. Wang L, Wang X, Proud CG. Activation of mRNA translation in rat cardiac myocytes to insulin involves multiple rapamycin-sensitive steps. Am J Physiol. 2000;278:H1056-H1068.
31. Ishizuka T, Sakata N, Johnson GL, et al. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. Biochem Biophys Res Commun. 1997;230:386-391.
32. Haq S, Choukroun G, Kang ZB, et al. Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol. 2000:151:117-129.
33. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
34. Ventura HO, Malik FS, Mehra MR, et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol. 1997;12:375-381.
35. Golbaekdal K, Nielsen CB, Djurhuus JC, et al. Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs. Transplantation. 1994;58:1153-1157.